GlassScriptPhysician profile
Julia P Neckman
NPI 1639478464
$2,521.20
in general payments reported to CMS, 2019-2025
22 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $285 · 2021: $170 · 2022: $274 · 2023: $516 · 2024: $581 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $536.74 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $490.94 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $400.03 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $179.48 | 2019-2025 | |
| Leo Pharma INC. | $134.48 | 2019-2025 | Anzupgo, Adbry |
| Organogenesis INC. | $128.97 | 2023-2025 | Puraply, Puraply Wound Matrix |
| Amgen INC. | $111.63 | 2021-2023 | Enbrel, Otezla |
| Sun Pharmaceutical Industries INC. | $75.72 | 2023-2024 | Winlevi |
| Pfizer INC. | $64.81 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $52.44 | 2021-2025 | |
| Kerecis Limited | $47.88 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Biofrontera INC. | $39.58 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $38.37 | 2022-2025 | Opzelura |
| Botanix Sb INC | $37.69 | 2025 | Sofdra |
| Organon LLC | $31.19 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $24.95 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.38 | 2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $24.07 | 2024 | Ycanth |
| Almirall LLC | $23.63 | 2019 | |
| Bioventus LLC | $20.05 | 2022 | |
| Allergan, INC. | $17.46 | 2019 | |
| Lilly USA, LLC | $16.71 | 2024 | Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Neckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.